‘Urine’ trouble now: bladder bid Targacept’s next hope post-fail
Targacept Inc.’s Phase II blowup of TC-5619 in schizophrenia, months after its fizzle in attention deficit hyperactivity disorder (ADHD), nixed the development program and turned investor eyes to a separate therapy for overactive bladder (OAB), also in Phase II, due to report data in the middle of next year.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST